Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.89 |
| ▸ | CA12 | O43570 | 3/20 | 0.89 |
| ▸ | CA1 | P00915 | 3/20 | 0.89 |
| ▸ | CA2 | P00918 | 3/20 | 0.89 |
| ▸ | CA7 | P43166 | 3/20 | 0.89 |
| ▸ | CA9 | Q16790 | 3/20 | 0.89 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.89 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.89 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.65 |
| ▸ | KDR | P35968 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylparaben SCHEMBL5311680 | 0.94 | CA12 (1.00) | ESR1CA12CA1CA2CA7 | |
| Ethylparaben SCHEMBL28368 | 0.94 | CA12 (1.00) | ESR1CA12CA1CA2CA7 | |
| Ethylparaben SCHEMBL475792 | 0.92 | CA12 (0.96) | ESR1CA12CA1CA2CA7 | |
| Ethylparaben SCHEMBL31655760 | 0.92 | CA12 (0.96) | ESR1CA12CA1CA2CA7 | |
| Ethylparaben SCHEMBL29290346 | 0.92 | CA12 (0.96) | ESR1CA12CA1CA2CA7 | |
| Ethylparaben SCHEMBL23497074 | 0.92 | CA12 (0.96) | ESR1CA12CA1CA2CA7 | |
| Ethylparaben SCHEMBL476012 | 0.92 | CA12 (0.96) | ESR1CA12CA1CA2CA7 | |
| Ethylparaben SCHEMBL31347872 | 0.92 | CA12 (0.96) | ESR1CA12CA1CA2CA7 | |
| Ethylparaben SCHEMBL29810737 | 0.92 | CA12 (0.96) | ESR1CA12CA1CA2CA7 | |
| Ethylparaben SCHEMBL29374744 | 0.92 | CA12 (0.96) | ESR1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1102040-A | — | — | None | — | — | JP | disclosed |
| EP-3965738-B1 | METHOD FOR PRODUCTION OF LIPOSOMES | UNIV DO MINHO (PT) | 2025-08-06 | — | — | EP | disclosed |
| US-20250197353-A1 | METHOD OF FORMING BOND BY COUPLING REACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-06-19 | — | — | US | disclosed |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| EP-4410775-A1 | METHOD FOR FORMING BOND THROUGH COUPLING REACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-08-07 | — | — | EP | disclosed |
| US-20240217992-A1 | RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | Jiangxi Kerui Pharmaceutical Co., Ltd. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217992-A1 | RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | Jiangxi Kerui Pharmaceutical Co., Ltd. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217992-A1 | RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | Jiangxi Kerui Pharmaceutical Co., Ltd. (CN) | 2024-07-04 | — | — | US | disclosed |
| CN-113661422-B | Polarizer and image display device | 富士胶片株式会社 | 2024-06-04 | — | — | CN | disclosed |
| CN-118043308-A | Bond formation method based on coupling reaction | 中外制药株式会社 | 2024-05-14 | — | — | CN | disclosed |
| US-4877858-A | FERROELECTRICAL HIG SPEED RESPONSE; DISPLAYS | IDEMETSU KOSAN CO., LTD. (JP) | 1989-10-31 | — | — | US | disclosed |
| US-4844835-A | FAST RESPONSE, DISPLAYING MOTION PICTURES | IDENITSU KOSAN CO., LTD. (JP) | 1989-07-04 | — | — | US | disclosed |
| US-4834907-A | STABLE, HIGH RESPONSE RATE | CHISSO CORPORATION (JP) | 1989-05-30 | — | — | US | disclosed |
| EP-0312210-A2 | Optically active liquid crystalline compounds and compositions containing them | CHISSO CORPORATION (JP) | 1989-04-19 | — | — | EP | disclosed |
| JP-H01102040-A | NOVEL OPTICALLY ACTIVE LIQUID CRYSTAL COMPOUND AND COMPOSITION | CHISSO CORP | 1989-04-19 | — | — | JP | disclosed |
| EP-0301587-A1 | Liquid crystal compounds and intermediates thereof | WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) | 1989-02-01 | — | — | EP | disclosed |
| US-4778621-A | Ester compound | CHISSO CORPORATION (JP) | 1988-10-18 | — | — | US | disclosed |
| EP-0228703-A2 | Ferroelectric liquid crystal polymer | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1987-07-15 | — | — | EP | disclosed |
| EP-0219958-A2 | Ferroelectric liquid crystal ester compound and liquid crystal composition | Chisso Corporation (JP) | 1987-04-29 | — | — | EP | disclosed |
| EP-0164814-A2 | Liquid crystalline ester compounds and mixtures thereof | Chisso Corporation (JP) | 1985-12-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217992-A1 | RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | RARA, RARG, RXRG | ESR1 452/4885CA12 3640/4885CA1 4533/4885 |
| US-12312316-B2 | Compounds and methods for the targeted degradation of androgen receptor | AR, MDM2, ESRRA | ESR1 61/4885CA12 2708/4885CA1 2519/4885 |
| US-20250197353-A1 | METHOD OF FORMING BOND BY COUPLING REACTION | CBR1, CBR3, NOX4 | ESR1 398/4885CA12 349/4885CA1 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.